[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335417-105":59,"doc-detail-335417-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","patient-specific-nanoparticle-targeting-in-human-leukemia-blood","Patient-Specific Nanoparticle Targeting in Human Leukemia Blood","","Antibody-directed targeting of chemotherapeutic nanoparticles to primary human cancers offers potential to enhance efficacy and limit off-target toxicity, yet clinical responses vary greatly across individuals. Using a matrix of nine particle formulations and an ex vivo whole-blood assay with 15 chronic lymphocytic leukemia (CLL) patients, the study shows that anti-CD20 functionalized PEG nanoparticles preferentially target CLL cells and reduce off-target phagocytosis variability.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patient-specific-nanoparticle-targeting-in-human-leukemia-blood/335417/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patient-specific-nanoparticle-targeting-in-human-leukemia-blood/335417.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was patient-specific nanoparticle targeting studied in this work?","Question",{"text":112,"@type":113},"The researchers prepared a nine-particle matrix and used an ex vivo whole-blood model with samples from 15 CLL patients to evaluate how nanoparticles target CLL cells and interact with immune cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What nanoparticle design showed efficient targeting of CLL cells?",{"text":117,"@type":113},"Anti-CD20 functionalized poly(ethylene glycol) (PEG) nanoparticles efficiently targeted CLL cells and resulted in relatively low off-target phagocytosis by granulocytes and monocytes.",{"name":119,"@type":110,"acceptedAnswer":120},"Which immune factors were linked to variability in PEGylated nanoparticle targeting?",{"text":121,"@type":113},"Variance in off-target association of PEGylated liposomes with granulocytes and monocytes significantly correlated with anti-PEG immunoglobulin G levels, and a negative correlation was observed between CLL targeting of PEG particles and anti-PEG immunoglobulin M levels.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335417,1790669050,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","This article is licensed under CC-BY-NC-ND 4.0  \n[www.acsnano.org](www.acsnano.org)  \nPatient-Specific Nanoparticle Targeting in Human Leukemia Blood  \nYi Ju,* Shiyao Li, Abigail Er Qi Tan, Emily H. Pilkington, Paul T. Brannon, Magdalena Plebanski, Jiwei Cui, Frank Caruso, Kristofer J. Thurecht, Constantine Tam, and Stephen J. Kent*  \n Cite This: ACS Nano 2024, 18, 29021−29035  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Antibody-directed targeting of chemotherapeutic nanoparticles to primary human cancers holds promise for improving efficacy and reducing off-target toxicity. However, clinical responses to targeted nanomedicines are highly variable. Herein, we prepared and examined a matrix of 9 particles (organic and inorganic particles of three surface chemistries with and without antibody functionalization) and developed an ex vivo model to study the person-specific targeting of nanoparticles in whole blood of 15 patients with chronic lymphocytic leukemia (CLL). Generally, anti-CD20-functionalized poly(ethylene glycol) (PEG) nanoparticles efficiently targeted CLL cells, leading to low off-target phagocytosis by granulocytes and monocytes in the blood. However, there was up to 164-fold patient-  \nto-patient variability in the CLL targeting. This was further exemplified through using clinically relevant PEGylateddoxorubicin-encapsulated liposomes, which showed high interpersonal differences in CLL targeting (up to 234-fold differences) and off-target phagocytosis (up to 65-and 112-fold differences in granulocytes and monocytes, respectively). Offtarget phagocytosis led to almost all monocytes being killed within 24 h of treatment. Variance of the off-target association of PEGylated liposomes with granulocytes and monocytes significantly correlated to anti-PEG immunoglobulin G levels in the blood of CLL patients. A negative correlation between CLL targeting of PEG particles and anti-PEG immunoglobulin M levels was found in the blood. Taken together, our study identifies anti-PEG antibodies as key proteins in modulating patient-specific targeting of PEGylated nanoparticles in human leukemia blood. Other factors, such as the antigen expression of targeted cells and fouling properties of nanoparticles, also play an important role in patient-specific targeting. The human leukemia blood assay we developed provides an ex vivo model to evaluate interpersonal variances in response to targeted nanomedicines. KEYWORDS: human blood model, off-targeting cytotoxicity, biomolecular coronas, immunoglobulins, precision medicine, particle−immune cell interactions  \nS  \npecific tumor targeting by nanoparticles to increase the efficacy of anticancer therapies and reduce off-target effects has been a long-held goal. Recurring issues for  \nnanoparticles are their off-target uptake, clearance, and cytotoxicity to phagocytes such as circulating neutrophils and monocytes.1 Immune suppression is the major dose-limiting and life-threatening toxicity of chemotherapeutics.2 A challenge for cancer treatments is providing a more favorable  \nbalance between antitumor activity and off-target toxicity.  \nEfficient targeting of nanoparticles to human cancers is yet to be realized, and improved models of targeting nanoparticles to human cancers are needed to achieve this goal.3 Recent work has shown the high targeting efficiency of immortalized leukemic cell lines in vitro and their efficacy in leukemic cell line-engrafted immunodeficient mice.4,5 However, in vitro studies of tumor cell lines have yet to capture the complexities of targeting primary human cancers in the presence of  \nautologous bystander cells. Furthermore, inbred mouse models typically have restricted immune systems that are developed in pathogen-free environments and rely on the induction or transplantation of tumors on a highly immunodeficient background, which","cbCaidgxsvfdEXPg","https://ap.wps.com/l/cbCaidgxsvfdEXPg","pdf",7415236,15,"English","# Abstract\n## Patient-specific targeting in whole blood\n## Particle matrix and antibody functionalization\n## Off-target phagocytosis and immunoglobulin correlations\n## Ex vivo assay value for precision medicine","[{\"question\":\"How was patient-specific nanoparticle targeting studied in this work?\",\"answer\":\"The researchers prepared a nine-particle matrix and used an ex vivo whole-blood model with samples from 15 CLL patients to evaluate how nanoparticles target CLL cells and interact with immune cells.\"},{\"question\":\"What nanoparticle design showed efficient targeting of CLL cells?\",\"answer\":\"Anti-CD20 functionalized poly(ethylene glycol) (PEG) nanoparticles efficiently targeted CLL cells and resulted in relatively low off-target phagocytosis by granulocytes and monocytes.\"},{\"question\":\"Which immune factors were linked to variability in PEGylated nanoparticle targeting?\",\"answer\":\"Variance in off-target association of PEGylated liposomes with granulocytes and monocytes significantly correlated with anti-PEG immunoglobulin G levels, and a negative correlation was observed between CLL targeting of PEG particles and anti-PEG immunoglobulin M levels.\"}]","Patient-Specific Nanoparticle Targeting in Human Leukemia Blood | PDF",1790010908,38]